Predictors of Hepatitis B Treatment Response in People with HIV-1/HBV coinfection Avihingsanon et al

  This content is only accessible to healthcare professionals in Belgium.   To view our restricted content please register HERE. You will be granted immediate access. If you are already registered, please sign-in HERE. To register as a Gilead employee,...

Week 52 Subgroup Efficacy of Lenacapavir in Heavily Treatment-Experienced PLWH Ogbuagu et al

  This content is only accessible to healthcare professionals in Belgium.   To view our restricted content please register HERE. You will be granted immediate access. If you are already registered, please sign-in HERE. To register as a Gilead employee,...

CROI 2023

  This content is only accessible to healthcare professionals in Belgium.   To view our restricted content please register HERE. You will be granted immediate access. If you are already registered, please sign-in HERE. To register as a Gilead employee,...

A retrospective, multicenter study on the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy^®) for the treatment of HIV in a real-world setting in Belgium Nasreddine et al.

  This content is only accessible to healthcare professionals in Belgium.   To view our restricted content please register HERE. You will be granted immediate access. If you are already registered, please sign-in HERE. To register as a Gilead employee,...

Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy^®) for the treatment of People Living with HIV: 24-Month Analyses by Age, Race, Sex, Adherence and Late Diagnosis in a Multi-Country Cohort Study Trottier et al.

  This content is only accessible to healthcare professionals in Belgium.   To view our restricted content please register HERE. You will be granted immediate access. If you are already registered, please sign-in HERE. To register as a Gilead employee,...

Outcomes After Switching From 144 Weeks of Blinded DTG/ABC/3TC or DTG + FTC/TAF to 96 Weeks of Open-label Biktarvy^® Orkin et al.

  This content is only accessible to healthcare professionals in Belgium.   To view our restricted content please register HERE. You will be granted immediate access. If you are already registered, please sign-in HERE. To register as a Gilead employee,...

HIV Glasgow 2022

  This content is only accessible to healthcare professionals in Belgium.   To view our restricted content please register HERE. You will be granted immediate access. If you are already registered, please sign-in HERE. To register as a Gilead employee,...

5-Year Outcomes of Biktarvy^® as Initial Treatment of HIV-1 in Adults With High Baseline HIV-1 RNA and/or Low CD4 Count in Two Phase 3 Randomized Clinical Trials Ramgopal et al.

  This content is only accessible to healthcare professionals in Belgium.   To view our restricted content please register HERE. You will be granted immediate access. If you are already registered, please sign-in HERE. To register as a Gilead employee,...

IDWeek 2022

  This content is only accessible to healthcare professionals in Belgium.   To view our restricted content please register HERE. You will be granted immediate access. If you are already registered, please sign-in HERE. To register as a Gilead employee,...

48-week data from ALLIANCE

  This content is only accessible to healthcare professionals in Belgium.   To view our restricted content please register HERE. You will be granted immediate access. If you are already registered, please sign-in HERE. To register as a Gilead employee,...

Week 48 Results of a Phase 3 Randomized Controlled Trial of Biktarvy^® vs DTG + FTC/TDF as Initial Treatment in Adults with HIV/HBV Coinfection (ALLIANCE) Avihingsanon et al.

  This content is only accessible to healthcare professionals in Belgium.   To view our restricted content please register HERE. You will be granted immediate access. If you are already registered, please sign-in HERE. To register as a Gilead employee,...

Long-term Integrated Analysis of Biktarvy^® in Treatment-Naïve adults With HIV Through Five Years of Follow-up Sax et al.

  This content is only accessible to healthcare professionals in Belgium.   To view our restricted content please register HERE. You will be granted immediate access. If you are already registered, please sign-in HERE. To register as a Gilead employee,...